Stock VIGL VIGIL NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Market Closed - Nasdaq
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
3.485 USD -4.78% Intraday chart for Vigil Neuroscience, Inc. -7.80% +3.11%
05-07 Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-17 Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
GL
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
GL
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
GL
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
AQ
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
GL
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
AQ
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
GL
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
GL
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
GL
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
AQ
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
GL
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
GL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
GL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
AQ
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
GL
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIGL Stock
  4. News Vigil Neuroscience, Inc.
  5. Press Releases